

## Genomics England GeCIP Steering Committee Meeting

Minutes of meeting held on 29<sup>th</sup> March 2016

**Chair:** Mark Caulfield (**MC**)

**In Attendance:** Phil Beales (**PB**), Guy Chung-Faye (**GCF**), Colin Cooper (**CC**), Adrienne Flanagan (**AF**), Tom Fowler (**TF**), Daniel Gale (**DG**), Dina Halai (**DH**), Henry Houlden (**HH**), Tim Hubbard (**TH**), Gkikas Magiorkinis (**GM**), Diana Baralle (**DM**), Stephen O'Rahilly (**SO**), Michael Parker (**MP**), Matina Prapa (**MPr**), Augusto Rendon (**AR**), Richard Scott (**RS**), Ellen Thomas (**ET**), Simon Thompson (**ST**), Clare Turnbull (**CT**), Anna Schuh (**AS**), Kate Witkowska (**KW**), Sarah Wordsworth (**SW**), Caroline Wright (**CW**)

**Called in:** Eric Alton (**EA**), Mark John Bale (**MB**), Maria Bitner-Glindzicz (**MBG**), Johann de Bono (**JB**), Maxine Foster (**MF**), Muhammad Kassim Javaid (**MKJ**), Judith Marsh (**JM**), John McGrath (**JMc**), Bill Newman (**BN**), Eamonn Sheridan (**ES**), Michael Simpson (**MS**), Ian Tomlinson (**IT**)

**Apologies:** Emma Baple, Nick Maltby, Ewan Birney, Bernard Keavney, James Larkin, Nick Turner, Josef Vormoor, Jenny Mansfield, Elijah Behr

### 1. Introduction

MC opened the meeting and welcomed everyone to the first meeting of the Committee.

MC informed the Committee of the following updates:

- Cancer Main Programme went live on 16<sup>th</sup> February 2016 and recruitment has now commenced with nominal genome allocations for each tumour type
- Cancer Pilot Programme provided useful information on DNA quality and the Cancer Main Programme will focus on fresh frozen tissue
- There are currently efforts in optimising biopsy processing pathways and DNA extraction and also on the consent structures to use diagnostic material
- Rare Disease Main Programme recruitment numbers were shared and the Committee were encouraged to work on recruiting to those diseases where recruitment is low
- Recruitment to the intellectual disability group has not been capped as initially there was broad eligibility, but now these recruits may map to other disease groups
- Analysis of data from the Rare Disease pilot programme has begun

- The Infectious Diseases Pilot Programme is working on a collaborative project with Genome British Columbia focusing on optimising analysis and clinical use of data
- The Validation and Feedback GeCIP have formed two Working Groups focused on cancer and rare disease working on clinical data quality and diagnostic efficiency
- Access to the datacentre will be towards the end of July 2016
- It has been decided that the Health & Social Care Information Centre (HSCIC) will manage identifiable patient data for Genomics England (GeL) according to GeL procedures
- There is capacity for additional sequencing over and above genomes allocated using the financial infrastructure set up by GeL, however domains will have to seek funding for this

## 2. GeCIP update

MC informed the Committee of their role and of the GeCIP Board:

- The GeCIP Board is Chaired by Professor Dame Kay Davies, they meet twice yearly with a focus for co-ordination of GeCIP activities. The GeCIP Steering Committee will report directly to the board with a representative from each GeCIP (cancer, rare disease and cross-cutting) sitting on the Board
- Funders (NIHR, MRC, Wellcome Trust, and CRUK) of the 100,000 Genomes Project sit on the Board and see GeCIP research proposals for potential funding
- Under instruction from the government, IP will be owned by Genomics England and the IP policy is being finalised. Genomics England will hold patents on behalf of the tax payer, however researchers will hold exclusive licence to develop the idea and gain commercial benefits working with GeL
- The GeCIP Steering Committee were invited to decide on a proposal to divide the Committee into cancer, rare disease and cross-cutting specific Committees in addition to one or two unified meetings where all assemble. It was concluded that GeCIP Domain leads would attend the existing Cancer and Rare Disease Working Groups with Cross-cutting Domain leads selecting which would be relevant for them. A Cross-cutting Working Group will also be set up.  
**ACTION: GeL to circulate Cancer, Rare Disease and Cross-cutting Working Group meeting agendas to the relevant Domain leads so that they may decide if attending these meetings would be valuable.**
- The Committee were reminded to acknowledge funding in publications, GeL provided a statement. Publications should be agreed between researchers, if there are disagreements or issues then publications will be brought to GeLs Publication Committee
- A proposed nine month publication moratorium was presented which will allow all GeCIP members to see all data however only those who have registered intended research analysis can publish on that topic for the first nine months. GeCIP members wishing to work on the same data should collaborate

ST updated on the current state of GeCIPs and the Collaboration Platform:

- Currently there are more than 2300 registered GeCIP members with the majority from UK academic institutions
- There 39 Domains equally split between cancer, rare disease and cross-cutting arms
- In order to access data, GeCIP members must complete the enrolment process

- A new version of the Participation Agreement will be circulated once the IP policy has been finalised
- The Collaboration Platform is an online environment to facilitate collaboration within domains, between domains, GMC:GeCIP and GENE:GeCIP. The environment has been established in the embassy with template pages currently in construction. GeL are looking to bring in testing groups
- AS highlighted that it would be useful to have existing analysis tools within the data centre

KW presented an update on the detailed research plans and the Omics Working Group:

- The review process of the research plans was outlined. Detailed feedback on the submitted research plans are to be circulated soon
- MC emphasised that GeL cannot provide additional funding/resources based on these research plans, additional funding will have to be applied for via response mode funding directly to funders
- The Omics Working Group is comprised of GeCIP experts to consult on the pilot phase. Collection of samples has commenced with the initial aim to analyse sample quality and consider timelines

MPr presented on the GeCIP webpage and upcoming meetings:

- The GeL website has been updated with more information for GeCIP members
- The HEE Education & Training meeting is provisionally scheduled for 7<sup>th</sup> June
- A GeCIP Conference is proposed to take place towards the beginning of 2017. The Committee expressed support for such an event

### **3. Recruitment update**

- MPr briefly presented the rare disease recruitment numbers and the Committee were encouraged to help recruit into the rare disease phenotypes with low recruitment
- ST informed that a total of 675 cancer samples have been collected

### **4. Bioinformatics Update**

- TH presented on the Fair Use Policy which outlines that GeL is able to provide a certain amount of compute and storage and provides guidance on how these will be administered. The compute power allocation trading scheme is yet to be finalised
- AR outlined the computer infrastructure GeL has in place and has plans to support as well as the kind of data that GeL will make available to GeCIP members

### **5. Elect GeCIP board representatives**

- It was decided that the election will take place online following this meeting

## **6. AOB**

- MC informed the Committee that, in due course, they will be invited to contribute to the next meeting agenda and to guide GeL on the items they wish to discuss and be informed on
- MC thanked all for attending and closed the meeting

**The date of the next meeting TBC**